© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Dana-Farber Cancer Institute
April 26, 2021
Multiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.
An expert hematologist-oncologist provides his perspective on the importance of managing toxicities in patients with relapsed/refractory multiple myeloma.
Clifton C. Mo, MD, reviews the ongoing multicenter phase 1 STOMP trial in relapsed/refractory multiple myeloma.
An expert hematologist-oncologist reviews the randomized, phase 3 BOSTON trial of a selinexor-based triplet regimen for the treatment of multiple myeloma.
Dr Clifton Mo describes second-line treatment options for the management of multiple myeloma, and treatment approaches for IMiD- and anti-CD38–refractory MM.
An expert hematologist-oncologist reviews the standard of care for transplant-eligible and transplant-ineligible patients with newly diagnosed MM and explores the role of quadruplet induction regimens.